Equity Overview
Price & Market Data
Price: $6.83
Daily Change: +$0.13 / 1.90%
Daily Range: $6.66 - $6.84
Market Cap: $50,017,156
Daily Volume: 52,261
Performance Metrics
1 Week: 8.41%
1 Month: 10.34%
3 Months: 9.98%
6 Months: 75.13%
1 Year: 6.72%
YTD: 8.59%
Company Details
Employees: 55
Sector: Health technology
Industry: Biotechnology
Country:
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.